Development
Alnylam Pharmaceuticals, Inc.
ALNY
$300.83
-$7.17-2.33%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 76.23% | 79.37% | 39.94% | 29.94% | 22.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 76.23% | 79.37% | 39.94% | 29.94% | 22.88% |
| Cost of Revenue | 83.87% | 77.70% | 58.50% | 29.96% | 20.46% |
| Gross Profit | 74.75% | 79.69% | 36.24% | 29.94% | 23.36% |
| SG&A Expenses | 3.24% | 8.19% | 29.35% | 27.31% | 24.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.80% | 18.61% | 29.07% | 24.69% | 17.36% |
| Operating Income | 64.06% | 55.20% | -15.62% | -17.79% | -10.78% |
| Income Before Tax | 61.53% | 57.40% | -8.27% | -18.80% | -32.25% |
| Income Tax Expenses | 61.54% | 279.34% | 86.19% | 657.63% | 512.21% |
| Earnings from Continuing Operations | 61.08% | 56.87% | -8.44% | -19.27% | -32.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 61.08% | 56.87% | -8.44% | -19.27% | -32.64% |
| EBIT | 64.06% | 55.20% | -15.62% | -17.79% | -10.78% |
| EBITDA | 69.20% | 60.04% | -15.21% | -18.31% | -12.03% |
| EPS Basic | 61.98% | 57.83% | -5.60% | -16.35% | -29.22% |
| Normalized Basic EPS | 59.98% | 54.54% | 0.53% | -9.76% | -9.08% |
| EPS Diluted | 61.73% | 57.48% | -5.61% | -16.35% | -29.32% |
| Normalized Diluted EPS | 59.23% | 53.83% | 0.53% | -9.76% | -9.08% |
| Average Basic Shares Outstanding | 2.65% | 2.90% | 2.92% | 2.80% | 2.73% |
| Average Diluted Shares Outstanding | 3.90% | 4.17% | 2.92% | 2.80% | 2.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |